Carcinoid syndrome laboratory tests: Difference between revisions
No edit summary |
No edit summary |
||
| Line 5: | Line 5: | ||
==Overview== | ==Overview== | ||
==Laboratory Findings== | |||
With a certain degree of clinical suspicion, [[diagnosis]] is made primarily by measuring plasma levels of the secreted glycoprotein Chromogranin A, supported by measuring the 24 hour [[urine]] levels of [[5-HIAA]] (5-hydroxyindoleacetic acid), a breakdown product of serotonin. Patients with carcinoid syndrome usually excrete >25 mg of 5-HIAA per day. | With a certain degree of clinical suspicion, [[diagnosis]] is made primarily by measuring plasma levels of the secreted glycoprotein Chromogranin A, supported by measuring the 24 hour [[urine]] levels of [[5-HIAA]] (5-hydroxyindoleacetic acid), a breakdown product of serotonin. Patients with carcinoid syndrome usually excrete >25 mg of 5-HIAA per day. | ||
Revision as of 16:23, 25 September 2012
Please help WikiDoc by adding more content here. It's easy! Click here to learn about editing.
|
Carcinoid syndrome Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Carcinoid syndrome laboratory tests On the Web |
|
American Roentgen Ray Society Images of Carcinoid syndrome laboratory tests |
|
Risk calculators and risk factors for Carcinoid syndrome laboratory tests |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Laboratory Findings
With a certain degree of clinical suspicion, diagnosis is made primarily by measuring plasma levels of the secreted glycoprotein Chromogranin A, supported by measuring the 24 hour urine levels of 5-HIAA (5-hydroxyindoleacetic acid), a breakdown product of serotonin. Patients with carcinoid syndrome usually excrete >25 mg of 5-HIAA per day.